Catatonia: Back to the future of the neuropsychiatric syndrome

Med Clin (Barc). 2022 Apr 22;158(8):369-377. doi: 10.1016/j.medcli.2021.10.015. Epub 2021 Dec 16.
[Article in English, Spanish]

Abstract

Catatonia is an undertreated and underdiagnosed neuropsychiatric syndrome whose prognosis is benign if treated early, thus avoiding possible complications and compromising the health of patients. The latest epidemiological studies indicate a prevalence of catatonia of 9.2%, being frequent in medical pathologies (especially neurological ones), as well as in psychiatric pathologies. The use of validated scales is recommended for its diagnosis, to be able to measure the severity and response to treatment. Once catatonia has been identified, it is necessary to perform a protocolized diagnostic study of the underlying aetiology («Catatonia Workup»). Treatment of choice is benzodiazepines and electroconvulsive therapy. In recent years, new therapeutic alternatives such as non-invasive transcranial magnetic stimulation have emerged. In this review we propose several initiatives to promote the dissemination and knowledge of catatonia in the clinical setting.

Keywords: COVID-19; Catatonia; Delirium; ECT; Lorazepam challenge test; Neuropsiquiatría; Neuropsychiatry; TEC; Test de lorazepam.

Publication types

  • Review

MeSH terms

  • Benzodiazepines / therapeutic use
  • Catatonia* / diagnosis
  • Catatonia* / epidemiology
  • Catatonia* / etiology
  • Electroconvulsive Therapy*
  • Humans
  • Prognosis
  • Syndrome

Substances

  • Benzodiazepines